FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies and potential cures for chronic diseases, has announced a significant financial move aimed at bolstering its operations. The company has entered into definitive agreements for the purchase of an aggregate of 4,081,633 shares of common stock, alongside warrants allowing for the purchase of an equal number of shares. The deal, priced at $0.735 per share, is set to generate approximately $3.0 million in gross proceeds.
The transaction includes series A and short-term series B warrants, both with an exercise price of $0.735 per share. The series A warrants will be valid for five years post the stockholder approval date, while the short-term series B warrants will expire eighteen months after the same date. The company anticipates closing the private placement on or around June 29, 2026, pending the satisfaction of customary conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for this offering. FibroBiologics expressed intentions to channel the net proceeds into working capital and general corporate purposes. Importantly, the shares offered in this placement are not registered under the Securities Act, meaning they cannot be sold in the U.S. without compliance with regulatory requirements.
As a key player in the biotechnology sector, FibroBiologics holds over 270 patents issued and pending across various clinical pathways. These innovations target numerous chronic conditions, including wound healing, multiple sclerosis, and cancer, underpinning the firm’s commitment to advancing medical therapies through fibroblast technology.
In tandem with this announcement, FibroBiologics also included a cautionary statement highlighting that the forward-looking statements included in the communication are subject to risks and uncertainties. These encompass factors such as the company’s liquidity and operational capabilities, as well as the unpredictable nature of research and clinical trial outcomes.
The private placement offering represents an essential step for FibroBiologics as it seeks to strengthen its financial foundation and support its ambitious research and development initiatives aimed at tackling chronic diseases.
